PATENT CLAIM ANALYSIS

Application Number: 15945011
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "138100"]

Abstract:
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

Claim (Index 14):
The method of  claim 13 , wherein the cancer is melanoma, lung cancer, head and neck cancer, liver cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, endometrial cancer, esophageal cancer, soft tissue sarcoma, cholangiocarcinoma, or hepatocellular carcinoma.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 91.0
- Lexical Diversity: 1.2069
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15239959', '15232026', '16064727', '15005042', '14709514']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.789648780797846
- 35 USC 102 Novelty (BERT): 0.5244973664296559
- Combined Prediction Score: 0.763133639361027
- Mean Citation Score: 328.78834399999994
- Max Citation Score: 344.3392
- Similarity Product: 286.7804121967316

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test